

Vincenzo Leuzzi

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2781768/publications.pdf>

Version: 2024-02-01

124
papers

3,675
citations

159358

30
h-index

168136

53
g-index

128
all docs

128
docs citations

128
times ranked

4871
citing authors

#	ARTICLE	IF	CITATIONS
1	High Rate of Recurrent De Novo Mutations in Developmental and Epileptic Encephalopathies. American Journal of Human Genetics, 2017, 101, 664-685.	2.6	337
2	Key European guidelines for the diagnosis and management of patients with phenylketonuria. Lancet Diabetes and Endocrinology, 2017, 5, 743-756.	5.5	272
3	White matter pathology in phenylketonuria. Molecular Genetics and Metabolism, 2010, 99, S3-S9.	0.5	154
4	The Genetic Landscape and Epidemiology of Phenylketonuria. American Journal of Human Genetics, 2020, 107, 234-250.	2.6	138
5	Genes of Early-Onset Epileptic Encephalopathies: From Genotype to Phenotype. Pediatric Neurology, 2012, 46, 24-31.	1.0	114
6	Intra-Erythrocyte Infusion of Dexamethasone Reduces Neurological Symptoms in Ataxia Telangiectasia Patients: Results of a Phase 2 Trial. Orphanet Journal of Rare Diseases, 2014, 9, 5.	1.2	114
7	Guanidinoacetate methyltransferase (GAMT) deficiency: Outcomes in 48 individuals and recommendations for diagnosis, treatment and monitoring. Molecular Genetics and Metabolism, 2014, 111, 16-25.	0.5	111
8	Creatine depletion in a new case with AGAT deficiency: clinical and genetic study in a large pedigree. Molecular Genetics and Metabolism, 2002, 77, 326-331.	0.5	95
9	Consensus guideline for the diagnosis and treatment of tetrahydrobiopterin (BH4) deficiencies. Orphanet Journal of Rare Diseases, 2020, 15, 126.	1.2	85
10	GNAO1 encephalopathy. Neurology: Genetics, 2017, 3, e143.	0.9	84
11	Living with phenylketonuria in adulthood: The PKU ATTITUDE study. Molecular Genetics and Metabolism Reports, 2018, 16, 39-45.	0.4	67
12	Aromatic amino acid decarboxylase deficiency: Molecular and metabolic basis and therapeutic outlook. Molecular Genetics and Metabolism, 2019, 127, 12-22.	0.5	66
13	Phenomenology and clinical course of movement disorder in GNAO1 variants: Results from an analytical review. Parkinsonism and Related Disorders, 2019, 61, 19-25.	1.1	64
14	Quantitative determination of guanidinoacetate and creatine in dried blood spot by flow injection analysis-electrospray tandem mass spectrometry. Clinica Chimica Acta, 2006, 364, 180-187.	0.5	61
15	Positive effect of erythrocyte-delivered dexamethasone in ataxia-telangiectasia. Neurology: Neuroimmunology and Neuroinflammation, 2015, 2, e98.	3.1	59
16	AADC deficiency from infancy to adulthood: Symptoms and developmental outcome in an international cohort of 63 patients. Journal of Inherited Metabolic Disease, 2020, 43, 1121-1130.	1.7	59
17	Neurocognitive and neuroimaging outcome of early treated young adult PKU patients: A longitudinal study. Molecular Genetics and Metabolism, 2015, 115, 84-90.	0.5	58
18	Guanidinoacetate and Creatine plus Creatinine Assessment in Physiologic Fluids: An Effective Diagnostic Tool for the Biochemical Diagnosis of Arginine:Glycine Amidinotransferase and Guanidinoacetate Methyltransferase Deficiencies. Clinical Chemistry, 2002, 48, 1772-1778.	1.5	57

#	ARTICLE	IF	CITATIONS
19	Frequency and phenotypic spectrum of <i>KMT2B</i> dystonia in childhood: A single-center cohort study. <i>Movement Disorders</i> , 2019, 34, 1516-1527.	2.2	55
20	Inborn errors of creatine metabolism and epilepsy. <i>Epilepsia</i> , 2013, 54, 217-227.	2.6	54
21	Erythrocyte-mediated delivery of phenylalanine ammonia lyase for the treatment of phenylketonuria in BTBR-Pahenu2 mice. <i>Journal of Controlled Release</i> , 2014, 194, 37-44.	4.8	45
22	Treatment with L-Arginine improves neuropsychological disorders in a child with Creatine transporter defect. <i>Neurocase</i> , 2008, 14, 151-161.	0.2	44
23	Metabolic epilepsy: An update. <i>Brain and Development</i> , 2013, 35, 827-841.	0.6	43
24	A novel mouse model of creatine transporter deficiency. <i>F1000Research</i> , 2014, 3, 228.	0.8	42
25	Microdeletions of <i>ELP4</i> Are Associated with Language Impairment, Autism Spectrum Disorder, and Mental Retardation. <i>Human Mutation</i> , 2015, 36, 842-850.	1.1	41
26	A mouse model for creatine transporter deficiency reveals early onset cognitive impairment and neuropathology associated with brain aging. <i>Human Molecular Genetics</i> , 2016, 25, 4186-4200.	1.4	39
27	Newborn screening for homocystinurias: Recent recommendations versus current practice. <i>Journal of Inherited Metabolic Disease</i> , 2019, 42, 128-139.	1.7	37
28	Can untreated PKU patients escape from intellectual disability? A systematic review. <i>Orphanet Journal of Rare Diseases</i> , 2018, 13, 149.	1.2	36
29	<i>ATP1A2</i> and <i>ATP1A3</i> associated early profound epileptic encephalopathy and polymicrogyria. <i>Brain</i> , 2021, 144, 1435-1450.	3.7	35
30	Epilepsy in <i>KCNH1</i> -related syndromes. <i>Epileptic Disorders</i> , 2016, 18, 123-136.	0.7	34
31	Clinical and Biochemical Features in a Patient With Mitochondrial Fission Factor Gene Alteration. <i>Frontiers in Genetics</i> , 2018, 9, 625.	1.1	34
32	Psychiatric disorders in adolescent and young adult patients with phenylketonuria. <i>Molecular Genetics and Metabolism</i> , 2016, 117, 12-18.	0.5	32
33	<i>Caenorhabditis elegans</i> provides an efficient drug screening platform for <i>GNAO1</i> -related disorders and highlights the potential role of caffeine in controlling dyskinesia. <i>Human Molecular Genetics</i> , 2022, 31, 929-941.	1.4	32
34	The expanding spectrum of movement disorders in genetic epilepsies. <i>Developmental Medicine and Child Neurology</i> , 2020, 62, 178-191.	1.1	31
35	Adult cognitive outcomes in phenylketonuria: explaining causes of variability beyond average Phe levels. <i>Orphanet Journal of Rare Diseases</i> , 2019, 14, 273.	1.2	30
36	Report of Two Never Treated Adult Sisters with Aromatic L-Amino Acid Decarboxylase Deficiency: A Portrait of the Natural History of the Disease or an Expanding Phenotype?. <i>JIMD Reports</i> , 2014, 15, 39-45.	0.7	29

#	ARTICLE	IF	CITATIONS
37	The outcome of white matter abnormalities in early treated phenylketonuric patients: A retrospective longitudinal long-term study. <i>Molecular Genetics and Metabolism</i> , 2015, 116, 171-177.	0.5	27
38	Dystonia-Ataxia with early handwriting deterioration in COQ8A mutation carriers: A case series and literature review. <i>Parkinsonism and Related Disorders</i> , 2019, 68, 8-16.	1.1	25
39	Predictability and inconsistencies of cognitive outcome in patients with phenylketonuria and personalised therapy: the challenge for the future guidelines. <i>Journal of Medical Genetics</i> , 2020, 57, 145-150.	1.5	24
40	Delineating the neurological phenotype in children with defects in the <sc><i>ECHS1</i></sc> or <sc><i>HIBCH</i></sc> gene. <i>Journal of Inherited Metabolic Disease</i> , 2021, 44, 401-414.	1.7	23
41	Cognitive, adaptive, and behavioral features in Joubert syndrome. <i>American Journal of Medical Genetics, Part A</i> , 2016, 170, 3115-3124.	0.7	22
42	Childhood-onset dystonia-causing KMT2B variants result in a distinctive genomic hypermethylation profile. <i>Clinical Epigenetics</i> , 2021, 13, 157.	1.8	22
43	Insights into the expanding phenotypic spectrum of inherited disorders of biogenic amines. <i>Nature Communications</i> , 2021, 12, 5529.	5.8	21
44	Guanidinoacetate and creatine plus creatinine assessment in physiologic fluids: an effective diagnostic tool for the biochemical diagnosis of arginine:glycine amidinotransferase and guanidinoacetate methyltransferase deficiencies. <i>Clinical Chemistry</i> , 2002, 48, 1772-8.	1.5	21
45	In vivo effects of dexamethasone on blood gene expression in ataxia telangiectasia. <i>Molecular and Cellular Biochemistry</i> , 2018, 438, 153-166.	1.4	20
46	Arginine and glycine stimulate creatine synthesis in creatine transporter 1-deficient lymphoblasts. <i>Analytical Biochemistry</i> , 2008, 375, 153-155.	1.1	19
47	Very early pattern of movement disorders in sepiapterin reductase deficiency. <i>Neurology</i> , 2013, 81, 2141-2142.	1.5	19
48	A novel compound heterozygous genotype associated with aromatic amino acid decarboxylase deficiency: Clinical aspects and biochemical studies. <i>Molecular Genetics and Metabolism</i> , 2019, 127, 132-137.	0.5	19
49	KCND3-Related Neurological Disorders: From Old to Emerging Clinical Phenotypes. <i>International Journal of Molecular Sciences</i> , 2020, 21, 5802.	1.8	19
50	<i>SUFU</i> haploinsufficiency causes a recognisable neurodevelopmental phenotype at the mild end of the Joubert syndrome spectrum. <i>Journal of Medical Genetics</i> , 2022, 59, 888-894.	1.5	19
51	Urine sepiapterin excretion as a new diagnostic marker for sepiapterin reductase deficiency. <i>Molecular Genetics and Metabolism</i> , 2015, 115, 157-160.	0.5	18
52	Erythrocyte-mediated delivery of recombinant enzymes. <i>Journal of Inherited Metabolic Disease</i> , 2016, 39, 519-530.	1.7	18
53	Development of global rating instruments for pediatric patients with ataxia telangiectasia. <i>European Journal of Paediatric Neurology</i> , 2016, 20, 140-146.	0.7	18
54	Predictability and inconsistencies in the cognitive outcome of early treated PKU patients. <i>Journal of Inherited Metabolic Disease</i> , 2017, 40, 793-799.	1.7	18

#	ARTICLE	IF	CITATIONS
55	A new therapy prevents intellectual disability in mouse with phenylketonuria. <i>Molecular Genetics and Metabolism</i> , 2018, 124, 39-49.	0.5	18
56	Pyridoxine-dependent epilepsies: an observational study on clinical, diagnostic, therapeutic and prognostic features in a pediatric cohort. <i>Metabolic Brain Disease</i> , 2018, 33, 261-269.	1.4	18
57	In vitro study of uptake and synthesis of creatine and its precursors by cerebellar granule cells and astrocytes suggests some hypotheses on the physiopathology of the inherited disorders of creatine metabolism. <i>BMC Neuroscience</i> , 2012, 13, 41.	0.8	17
58	Neurotransmitter trafficking defect in a patient with clathrin (CLTC) variation presenting with intellectual disability and early-onset parkinsonism. <i>Parkinsonism and Related Disorders</i> , 2019, 61, 207-210.	1.1	17
59	New pathogenic variants in COQ4 cause ataxia and neurodevelopmental disorder without detectable CoQ10 deficiency in muscle or skin fibroblasts. <i>Journal of Neurology</i> , 2021, 268, 3381-3389.	1.8	17
60	Behavioral and Neurochemical Characterization of New Mouse Model of Hyperphenylalaninemia. <i>PLoS ONE</i> , 2013, 8, e84697.	1.1	17
61	Untreated PKU Patients without Intellectual Disability: What Do They Teach Us?. <i>Nutrients</i> , 2019, 11, 2572.	1.7	16
62	Co-occurring WARS2 and CHRNA6 mutations in a child with a severe form of infantile parkinsonism. <i>Parkinsonism and Related Disorders</i> , 2020, 72, 75-79.	1.1	16
63	Progressive myoclonus epilepsy and ceroidlipofuscinosis 14: The multifaceted phenotypic spectrum of KCTD7-related disorders. <i>European Journal of Medical Genetics</i> , 2019, 62, 103591.	0.7	15
64	Impaired urinary concentration ability is a sensitive predictor of renal disease progression in Joubert syndrome. <i>Nephrology Dialysis Transplantation</i> , 2020, 35, 1195-1202.	0.4	15
65	<i>De novo DHDDS</i> variants cause a neurodevelopmental and neurodegenerative disorder with myoclonus. <i>Brain</i> , 2022, 145, 208-223.	3.7	15
66	Acute ischemic stroke in childhood: a comprehensive review. <i>European Journal of Pediatrics</i> , 2022, 181, 45-58.	1.3	15
67	Aromatic L-amino Acid Decarboxylase (AADC) deficiency: results from an Italian modified Delphi consensus. <i>Italian Journal of Pediatrics</i> , 2021, 47, 13.	1.0	15
68	A Nervous System-Specific Model of Creatine Transporter Deficiency Recapitulates the Cognitive Endophenotype of the Disease: a Longitudinal Study. <i>Scientific Reports</i> , 2019, 9, 62.	1.6	14
69	Parkinsonism in children: Clinical classification and etiological spectrum. <i>Parkinsonism and Related Disorders</i> , 2021, 82, 150-157.	1.1	14
70	A mutation on exon 6 of guanidinoacetate methyltransferase (GAMT) gene supports a different function for isoform a and b of GAMT enzyme. <i>Molecular Genetics and Metabolism</i> , 2006, 87, 88-90.	0.5	13
71	Severe early onset ethylmalonic encephalopathy with West syndrome. <i>Metabolic Brain Disease</i> , 2015, 30, 1537-1545.	1.4	13
72	ATM splicing variants as biomarkers for low dose dexamethasone treatment of A-T. <i>Orphanet Journal of Rare Diseases</i> , 2017, 12, 126.	1.2	13

#	ARTICLE	IF	CITATIONS
73	Brain <scp>MR</scp> patterns in inherited disorders of monoamine neurotransmitters: An analysis of 70 patients. <i>Journal of Inherited Metabolic Disease</i> , 2021, 44, 1070-1082.	1.7	13
74	Refining the mutational spectrum and geneâ€“phenotype correlates in pontocerebellar hypoplasia: results of a multicentric study. <i>Journal of Medical Genetics</i> , 2022, 59, 399-409.	1.5	13
75	Expanding the genetic and phenotypic spectrum of <scp><i>CHD2</i></scp>â€“related disease: From early neurodevelopmental disorders to adultâ€“onset epilepsy. <i>American Journal of Medical Genetics, Part A</i> , 2022, 188, 522-533.	0.7	13
76	<i>PRICKLE1</i>â€“related early onset epileptic encephalopathy. <i>American Journal of Medical Genetics, Part A</i> , 2018, 176, 2841-2845.	0.7	12
77	Treatable Inherited Movement Disorders in Children: Spotlight on Clinical and Biochemical Features. <i>Movement Disorders Clinical Practice</i> , 2020, 7, 154-166.	0.8	12
78	NGS in Hereditary Ataxia: When Rare Becomes Frequent. <i>International Journal of Molecular Sciences</i> , 2021, 22, 8490.	1.8	12
79	Italian national consensus statement on management and pharmacological treatment of phenylketonuria. <i>Orphanet Journal of Rare Diseases</i> , 2021, 16, 476.	1.2	12
80	Ataxia-telangiectasia. <i>Neurology: Genetics</i> , 2018, 4, e228.	0.9	11
81	Long-term clinical outcome of 6-pyruvoyl-tetrahydropterin synthase-deficient patients. <i>Molecular Genetics and Metabolism</i> , 2020, 131, 155-162.	0.5	11
82	The management of phenylketonuria in adult patients in Italy: a survey of six specialist metabolic centers. <i>Current Medical Research and Opinion</i> , 2021, 37, 411-421.	0.9	11
83	Biallelic mutations in <i>RNF220</i> cause laminopathies featuring leukodystrophy, ataxia and deafness. <i>Brain</i> , 2021, 144, 3020-3035.	3.7	11
84	Targeting mGlu5 Metabotropic Glutamate Receptors in the Treatment of Cognitive Dysfunction in a Mouse Model of Phenylketonuria. <i>Frontiers in Neuroscience</i> , 2018, 12, 154.	1.4	10
85	Genetic Neonatal-Onset Epilepsies and Developmental/Epileptic Encephalopathies with Movement Disorders: A Systematic Review. <i>International Journal of Molecular Sciences</i> , 2021, 22, 4202.	1.8	10
86	Compound heterozygosis in AADC deficiency: A complex phenotype dissected through comparison among heterodimeric and homodimeric AADC proteins. <i>Molecular Genetics and Metabolism</i> , 2021, 134, 147-155.	0.5	10
87	Age-Related Psychophysiological Vulnerability to Phenylalanine in Phenylketonuria. <i>Frontiers in Pediatrics</i> , 2014, 2, 57.	0.9	9
88	Clinical characterization of tremor in patients with phenylketonuria. <i>Molecular Genetics and Metabolism</i> , 2019, 128, 53-56.	0.5	9
89	Clinical variability at the mild end of <i>BRAT1</i>â€“related spectrum: Evidence from two families with genotypeâ€“phenotype discordance. <i>Human Mutation</i> , 2022, 43, 67-73.	1.1	9
90	Inborn errors of creatine metabolism and epilepsy: clinical features, diagnosis, and treatment. <i>Journal of Child Neurology</i> , 2002, 17 Suppl 3, 3S89-97; discussion 3S97.	0.7	9

#	ARTICLE	IF	CITATIONS
91	Development of a new UPLC-ESI-MS/MS method for the determination of biopterin and neopterin in dried blood spot. <i>Clinica Chimica Acta</i> , 2017, 466, 145-151.	0.5	8
92	Issues with European guidelines for phenylketonuria – Authors' reply. <i>Lancet Diabetes and Endocrinology</i> , 2017, 5, 683-684.	5.5	8
93	Urinary Neopterin and Phenylalanine Loading Test as Tools for the Biochemical Diagnosis of Segawa Disease. <i>JIMD Reports</i> , 2012, 7, 67-75.	0.7	7
94	Paradoxical sleep deprivation in rats causes a selective reduction in the expression of type-2 metabotropic glutamate receptors in the hippocampus. <i>Pharmacological Research</i> , 2017, 117, 46-53.	3.1	7
95	Parkinsonism, Intellectual Disability, and Catatonia in a Young Male With <i>MECP2</i> Variant. <i>Movement Disorders Clinical Practice</i> , 2020, 7, 118-119.	0.8	7
96	Cognitive Outcomes and Relationships with Phenylalanine in Phenylketonuria: A Comparison between Italian and English Adult Samples. <i>Nutrients</i> , 2020, 12, 3033.	1.7	7
97	Missense <i>PDSS1</i> mutations in CoenzymeQ10 synthesis cause optic atrophy and sensorineural deafness. <i>Annals of Clinical and Translational Neurology</i> , 2021, 8, 247-251.	1.7	7
98	Episodic ataxia and severe infantile phenotype in spinocerebellar ataxia type 14: expansion of the phenotype and novel mutations. <i>Journal of Neurology</i> , 2022, 269, 1476-1484.	1.8	7
99	Assessment of intellectual impairment, health-related quality of life, and behavioral phenotype in patients with neurotransmitter related disorders: Data from the <i>INTD</i> registry. <i>Journal of Inherited Metabolic Disease</i> , 2021, 44, 1489-1502.	1.7	7
100	Get Your Molar Tooth Right: Joubert Syndrome Misdiagnosis Unmasked by Whole-Exome Sequencing. <i>Cerebellum</i> , 2022, 21, 1144-1150.	1.4	7
101	Validity and reliability of Italian version of the Non-Communicating Children's Pain Checklist: revised version. <i>European Journal of Physical and Rehabilitation Medicine</i> , 2019, 55, 89-94.	1.1	6
102	A next generation sequencing-based analysis of a large cohort of ataxic patients refines the clinical spectrum associated with spinocerebellar ataxia 21. <i>European Journal of Neurology</i> , 2021, 28, 2784-2788.	1.7	6
103	Uniparental disomy of chromosome 1 unmasks recessive mutations of <i>PPT1</i> in a boy with neuronal ceroid lipofuscinosis type 1. <i>Brain and Development</i> , 2017, 39, 182-183.	0.6	5
104	Intellectual Disability and Brain Creatine Deficit: Phenotyping of the Genetic Mouse Model for <i>GAMT</i> Deficiency. <i>Genes</i> , 2021, 12, 1201.	1.0	4
105	Broadening phenotype of adenylosuccinate lyase deficiency: A novel clinical pattern resembling neuronal ceroid lipofuscinosis. <i>Molecular Genetics and Metabolism Reports</i> , 2019, 21, 100502.	0.4	3
106	<i>KCNQ2</i> encephalopathy manifesting with Rett-like features. <i>Neurology: Genetics</i> , 2020, 6, e510.	0.9	3
107	Executive functioning, adaptive skills, emotional and behavioral profile: A comparison between autism spectrum disorder and phenylketonuria. <i>Molecular Genetics and Metabolism Reports</i> , 2020, 23, 100577.	0.4	3
108	Multiple sclerosis and intracellular cobalamin defect (<i>MMACHC/PRDX1</i>) comorbidity in a young male. <i>Molecular Genetics and Metabolism Reports</i> , 2020, 22, 100560.	0.4	3

#	ARTICLE	IF	CITATIONS
109	Novel unconventional variants expand the allelic spectrum of OPHN1 gene. American Journal of Medical Genetics, Part A, 2021, 185, 1575-1581.	0.7	3
110	Presenting Patterns of Genetically Determined Developmental Encephalopathies With Epilepsy and Movement Disorders: A Single Tertiary Center Retrospective Cohort Study. Frontiers in Neurology, 0, 13, .	1.1	3
111	The Spectrum of Early Movement Disorders in Congenital Defects of Biogenic Amine Metabolism. Journal of Pediatric Neurology, 2015, 13, 213-224.	0.0	2
112	A novel developmental encephalopathy with epilepsy and hyperkinetic movement disorders associated with a deletion of the sodium channel gene cluster on chromosome 2q24.3. Parkinsonism and Related Disorders, 2019, 68, 1-3.	1.1	2
113	<i>AP1S2</i> truncating variant in a patient with severe neurodevelopmental disorder and cerebral folate deficiency. Acta Paediatrica, International Journal of Paediatrics, 2019, 108, 564-565.	0.7	2
114	TSC1 as a Novel Gene for Sleep-Related Hypermotor Epilepsy: A Child with a Mild Phenotype of Tuberous Sclerosis. Neuropediatrics, 2021, 52, 146-149.	0.3	2
115	Simultaneous determination of 5-hydroxytryptophan and 3-O-methyldopa in dried blood spot by UPLC-MS/MS: A useful tool for the diagnosis of L-amino acid decarboxylase deficiency. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 2021, 1185, 122999.	1.2	2
116	3-Methylglutaconic Aciduria Type I Due to AUH Defect: The Case Report of a Diagnostic Odyssey and a Review of the Literature. International Journal of Molecular Sciences, 2022, 23, 4422.	1.8	2
117	Running apraxia as a presenting symptom of neuronal ceroid lipofuscinosis 6. Movement Disorders, 2014, 29, 277-278.	2.2	1
118	Altered tetrahydrobiopterin metabolism in patients with phenylalanine hydroxylase deficiency. European Journal of Pediatrics, 2017, 176, 917-924.	1.3	1
119	Creatine Levels in Patients with Phenylketonuria and Mild Hyperphenylalaninemia: A Pilot Study. Life, 2021, 11, 425.	1.1	1
120	Engineering new metabolic pathways in isolated cells for the degradation of guanidinoacetic acid and simultaneous production of creatine. Molecular Therapy - Methods and Clinical Development, 2022, 25, 26-40.	1.8	1
121	Neurodevelopmental Impairment As the Main Phenotypic Hallmark Associated with the Translocation t(7;10)(7p22.3;q26.11). Journal of Pediatric Genetics, 2020, 11, 68-73.	0.3	0
122	Proteinuria in SLE: Is it always lupus? Lupus, 2021, 30, 664-668.	0.8	0
123	Functional Classification of the ATM Variant c.7157C>A and In Vitro Effects of Dexamethasone. Frontiers in Genetics, 2021, 12, 759467.	1.1	0
124	Looking back at the neonatal period in early-treated phenylketonuric patients. Pediatric Research, 2022, , .	1.1	0